Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte OptionMarketBeat · 2 days ago
Prelude Therapeutics to Participate in the Chardan Healthcare ConferenceGlobeNewsWire · Oct 16, 2026
Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a TurnaroundZacks Investment Research · Oct 16, 2026
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast CancerGlobeNewsWire · Oct 13, 2026
Head to Head Review: Surrozen (NASDAQ:SRZN) and Prelude Therapeutics (NASDAQ:PRLD)Defense World · Oct 12, 2026
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock Rated “Moderate Buy” by Sell-Side AnalystsDefense World · Oct 1, 2026Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.20 | -$0.14 | Beat |
| May 12, 2026 | -$0.27 | -$0.13 | Beat |
| Mar 10, 2026 | -$0.33 | -$0.20 | Beat |
| Nov 12, 2025 | -$0.35 | -$0.26 | Beat |
| Aug 14, 2025 | -$0.45 | -$0.41 | Beat |
| May 6, 2025 | -$0.47 | -$0.42 | Beat |